Lanthanum carbonate
- Generic Name
- Lanthanum carbonate
- Brand Names
- Fosrenol
- Drug Type
- Small Molecule
- Chemical Formula
- C3La2O9
- CAS Number
- 587-26-8
- Unique Ingredient Identifier
- 0M78EU4V9H
- Background
Lanthanum carbonate is a phosphate binder commonly used in clinical practice. It is marketed under the trade name Fosrenol by Shire Pharmaceuticals. It is the largest of all pills filled in community pharmacies. Sometimes patients forget that Fosrenol is not swallowed whole, but instead should be chewed. This has led to severe choking. It is prescribed for t...
- Indication
Used to reduce serum phosphate in patients with end stage renal disease (ESRD).
- Associated Conditions
- Hyperphosphataemia
- Associated Therapies
- -
Low Phosphate Diets in Patients With Early Stages of Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT00438932
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Lanthanum Carbonate in Reducing Serum Phosphorus Levels in Subjects With Stage 3 and 4 Chronic Kidney Disease
- First Posted Date
- 2005-10-07
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Shire
- Target Recruit Count
- 84
- Registration Number
- NCT00234702
- Locations
- 🇺🇸
VA Greater Los Angeles Health Care System, Los Angeles, California, United States
🇺🇸Northwest Renal Clinic, Portland, Oregon, United States
🇺🇸St. Louis University/Nephrology, Saint Louis, Missouri, United States
Efficacy and Safety of Fosrenol in Treating Elevated Serum Phosphate Levels in Adults With End Stage Renal Disease
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Shire
- Target Recruit Count
- 2500
- Registration Number
- NCT00160121
Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Shire
- Target Recruit Count
- 48
- Registration Number
- NCT00151918
Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving Dialysis
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Shire
- Target Recruit Count
- 456
- Registration Number
- NCT00151931
Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their Blood
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Shire
- Target Recruit Count
- 460
- Registration Number
- NCT00150566
A Long Term Study of Lanthanum Carbonate in Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate in Previous Studies Defined by the Protocol.
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Shire
- Target Recruit Count
- 93
- Registration Number
- NCT00150540
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.